Nasal Polyps (Nasal Polyposis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Nasal polyps (Nasal polyposis) is an inflammatory condition that develops in the nasal lining of the nose. They are non-cancerous growths. Signs and symptoms include runny nose, postnasal drip, headache, snoring, and loss of sense of taste. Risk factors include asthma, aspirin sensitivity, cystic fibrosis, Churg-Strauss syndrome, and allergic fungal sinusitis. Treatment includes steroid medications.

The Nasal Polyps (Nasal Polyposis) Drugs in Development market research report provides an overview of the Nasal Polyps (Nasal Polyposis) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nasal Polyps (Nasal Polyposis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasal Polyps (Nasal Polyposis) and features dormant and discontinued projects.

Nasal Polyps Pipeline Drugs Market Targets

The targets of the Nasal Polyps pipeline drugs market are Immunoglobulin E ), Interleukin 5 Receptor Subunit Alpha, Glucocorticoid Receptor, Interleukin 1 Receptor Like 1, Interleukin 33, Interleukin 4 Receptor Subunit Alpha, Interleukin 5, and Prostaglandin D2 Receptor 2.

Nasal Polyps pipeline drugs market, by targets

Nasal Polyps pipeline drugs market, by targets

For more target insights, download a free report sample

Mechanisms of Action of Nasal Polyps Pipeline Drugs Market

The mechanisms of action of the Nasal Polyps pipeline drugs market are Immunoglobulin E Inhibitor, Interleukin 5 Receptor Subunit Alpha Antagonist, Glucocorticoid Receptor Agonist, Interleukin 33 Inhibitor, Interleukin 4 Receptor Subunit Alpha Antagonist, Interleukin 5 Inhibitor, and Prostaglandin D2 Receptor 2 Antagonist.

Nasal Polyps pipeline drugs market, by mechanisms of action

Nasal Polyps pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

Routes of Administration in Nasal Polyps Pipeline Drugs Market

The routes of administration in the Nasal Polyps pipeline drugs market are subcutaneous, intravenous, nasal, and oral.

Nasal Polyps pipeline drugs market, by routes of administration

Nasal Polyps pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

Molecule Types in Nasal Polyps Pipeline Drugs Market

The molecule types in the Nasal Polyps pipeline drugs market are monoclonal antibody, small molecule, and biologic.

Nasal Polyps pipeline drugs market, by molecule types

Nasal Polyps pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Key Nasal Polyps Pipeline Drugs Market Companies

Some of the key companies in the Nasal Polyps pipeline drugs market are Kyowa Kirin Co Ltd, AnaptysBio Inc, Curateq Biologics Pvt Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Novartis AG, OptiNose Inc, Pfizer Inc, Suzhou Connect Biopharmaceuticals Ltd, and Synermore Biologics Co Ltd.

Nasal Polyps pipeline drugs market, by key companies

Nasal Polyps pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report overview

Targets Immunoglobulin E ), Interleukin 5 Receptor Subunit Alpha, Glucocorticoid Receptor, Interleukin 1 Receptor Like 1, Interleukin 33, Interleukin 4 Receptor Subunit Alpha, Interleukin 5, and Prostaglandin D2 Receptor 2
Mechanisms of Action Immunoglobulin E Inhibitor, Interleukin 5 Receptor Subunit Alpha Antagonist, Glucocorticoid Receptor Agonist, Interleukin 33 Inhibitor, Interleukin 4 Receptor Subunit Alpha Antagonist, Interleukin 5 Inhibitor, and Prostaglandin D2 Receptor 2 Antagonist
Routes of Administration Subcutaneous, Intravenous, Nasal, and Oral
Molecule Types Monoclonal Antibody, Small Molecule, and Biologic
Key Companies Kyowa Kirin Co Ltd, AnaptysBio Inc, Curateq Biologics Pvt Ltd, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Novartis AG, OptiNose Inc, Pfizer Inc, Suzhou Connect Biopharmaceuticals Ltd, and Synermore Biologics Co Ltd

Scope 

This report provides:

  • A snapshot of the global therapeutic landscape of Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders).
  • Reviews of pipeline therapeutics for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key companies involved in Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • Evaluation of Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) targeted therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

AnaptysBio Inc
Curateq Biologics Pvt Ltd
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Kyowa Kirin Co Ltd
Novartis AG
OptiNose Inc
Pfizer Inc
Suzhou Connect Biopharmaceuticals Ltd
Synermore Biologics Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Nasal Polyps (Nasal Polyposis) – Overview

Nasal Polyps (Nasal Polyposis) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Nasal Polyps (Nasal Polyposis) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nasal Polyps (Nasal Polyposis) – Companies Involved in Therapeutics Development

AnaptysBio Inc

Curateq Biologics Pvt Ltd

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Kyowa Kirin Co Ltd

Novartis AG

OptiNose Inc

Pfizer Inc

Suzhou Connect Biopharmaceuticals Ltd

Synermore Biologics Co Ltd

Nasal Polyps (Nasal Polyposis) – Drug Profiles

benralizumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

CBP-201 – Drug Profile

Product Description

Mechanism Of Action

History of Events

etokimab – Drug Profile

Product Description

Mechanism Of Action

History of Events

fevipiprant – Drug Profile

Product Description

Mechanism Of Action

History of Events

fluticasone propionate – Drug Profile

Product Description

Mechanism Of Action

History of Events

mepolizumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

omalizumab – Drug Profile

Product Description

Mechanism Of Action

History of Events

omalizumab biosimilar – Drug Profile

Product Description

Mechanism Of Action

History of Events

omalizumab biosimilar – Drug Profile

Product Description

Mechanism Of Action

PF-06817024 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Nasal Polyps (Nasal Polyposis) – Dormant Projects

Nasal Polyps (Nasal Polyposis) – Discontinued Products

Nasal Polyps (Nasal Polyposis) – Product Development Milestones

Featured News & Press Releases

Mar 15, 2022: FDA declines approval for AstraZeneca’s chronic rhinosinusitis antibody

Nov 08, 2021: NUCALA (mepolizumab) the first and only anti-IL-5 add-on treatment approved in Canada that targets eosinophilic inflammation in adults with chronic rhinosinusitis with nasal polyps (CRSwNP)

Sep 17, 2021: GSK receives CHMP positive opinions recommending approval of Nucala (mepolizumab) in three additional eosinophil-driven diseases

Sep 08, 2021: Connect Biopharma announces first subject dosed in phase 2 trial evaluating CBP-201 in adult patients with chronic rhinosinusitis with nasal polyps

Jul 29, 2021: GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps

Apr 12, 2021: Novartis receives FDA approval of Xolair (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients

Dec 08, 2020: FDA accepts GSK’s filing of Nucala (mepolizumab) for use in chronic rhinosinusitis with nasal polyps

Dec 01, 2020: Genentech announces FDA approval of Xolair (omalizumab) for adults with nasal polyps

Oct 29, 2020: GSK Nucala (mepolizumab) filings accepted by European Medicines Agency for three additional eosinophil-driven diseases

Sep 10, 2020: AstraZeneca reports positive results from OSTRO trial of Fasenra

Aug 10, 2020: AnaptysBio reports top-line data from interim analysis of ECLIPSE phase 2 clinical trial of Etokimab in chronic rhinosinusitis with nasal polyps

Aug 06, 2020: Novartis receives EC approval for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps

Jul 08, 2020: Optinose announces XHANCE co-promotion agreement with Kaléo

Jun 26, 2020: Novartis receives positive CHMP opinion for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps

Apr 03, 2020: Nucala (mepolizumab) is the first anti-IL5 biologic to report positive phase 3 results in patients with nasal polyps

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Nasal Polyps (Nasal Polyposis), 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Nasal Polyps (Nasal Polyposis) – Pipeline by AnaptysBio Inc, 2022

Nasal Polyps (Nasal Polyposis) – Pipeline by Curateq Biologics Pvt Ltd, 2022

Nasal Polyps (Nasal Polyposis) – Pipeline by F. Hoffmann-La Roche Ltd, 2022

Nasal Polyps (Nasal Polyposis) – Pipeline by GlaxoSmithKline Plc, 2022

Nasal Polyps (Nasal Polyposis) – Pipeline by Kyowa Kirin Co Ltd, 2022

Nasal Polyps (Nasal Polyposis) – Pipeline by Novartis AG, 2022

Nasal Polyps (Nasal Polyposis) – Pipeline by OptiNose Inc, 2022

Nasal Polyps (Nasal Polyposis) – Pipeline by Pfizer Inc, 2022

Nasal Polyps (Nasal Polyposis) – Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2022

Nasal Polyps (Nasal Polyposis) – Pipeline by Synermore Biologics Co Ltd, 2022

Nasal Polyps (Nasal Polyposis) – Dormant Projects, 2022

Nasal Polyps (Nasal Polyposis) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Nasal Polyps (Nasal Polyposis), 2022

Number of Products under Development by Companies, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage Top 10 Molecule Types, 2022

Frequently asked questions

Nasal Polyps (Nasal Polyposis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Nasal Polyps (Nasal Polyposis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Nasal Polyps (Nasal Polyposis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.